• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.

作者信息

Keating M J, McLaughlin P, Plunkett W, Robertson L E, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F

机构信息

Department of Hematology, University of Texas M. D. Anderson Cancer Center, Houston.

出版信息

Ann Oncol. 1994;5 Suppl 2:79-83. doi: 10.1093/annonc/5.suppl_2.s79.

DOI:10.1093/annonc/5.suppl_2.s79
PMID:8204523
Abstract

BACKGROUND

Fludarabine monophosphate (fludarabine) is an adenine nucleoside analogue active in indolent lymphoproliferative diseases which has an increasing role in studies incorporating combinations of agents which exploit biochemical modulation, inhibition of DNA repair, and radiosensitizing effects.

PATIENTS AND METHODS

Patients with lymphoma and chronic lymphocytic leukemia (CLL) treated at the M. D. Anderson Cancer Center (MDACC) and reports in the literature form the basis of this report.

RESULTS

CLL has traditionally been treated with alkylating agents and corticosteroids. In this study, fludarabine has shown marked cytoreductive ability in both previously treated patients and untreated patients. In the former group, there has been a 55% response rate in 374 patients, and 79% in the untreated CLL group. Fludarabine has also been very active in the management of low-grade lymphomas, with two-thirds of patients with follicular lymphoma and half of those with other indolent lymphomas responding. Waldenstrom's macroglobulinemia is also sensitive to the effects of fludarabine. Combination regimens were developed incorporating the substantial effectiveness of fludarabine and mitoxantrone where in the previously treated low-grade lymphoma group 25 of 28 patients (89%) responded. Fludarabine has the effect of increasing the triphosphate form of cytosine arabinoside in acute and chronic leukemic cells. This modulation has now been translated into therapy for acute leukemia and combined with cisplatinum in refractory CLL. Fludarabine inhibits DNA repair and enhances cross-linking of DNA by cisplatinum. The combination of fludarabine, ara-C, and cis-platinum is now being used in refractory CLL. Fludarabine is a radiation sensitizer, inhibiting repair of DNA damage. Studies are ongoing with this combination.

CONCLUSIONS

Fludarabine is a potent molecule with a wide range of biochemical effects. Optimal use of this drug alone and in combination is continuing to be explored.

摘要

相似文献

1
Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma.
Ann Oncol. 1994;5 Suppl 2:79-83. doi: 10.1093/annonc/5.suppl_2.s79.
2
The expanding role of fludarabine in hematologic malignancies.
Leuk Lymphoma. 1994;14 Suppl 2:11-6. doi: 10.3109/10428199409052690.
3
Purine analogs in chronic lymphocytic leukemia and Waldenström's macroglobulinemia.慢性淋巴细胞白血病和华氏巨球蛋白血症中的嘌呤类似物。
Ann Oncol. 1996;7 Suppl 6:S27-33. doi: 10.1093/annonc/7.suppl_6.s27.
4
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.利妥昔单抗联合氟达拉滨和环磷酰胺或其他药物治疗慢性淋巴细胞白血病。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1529-43. doi: 10.1586/era.10.132.
5
The role of fludarabine in hematological malignancies.
Blood Rev. 1994 Sep;8(3):125-34. doi: 10.1016/0268-960x(94)90072-p.
6
Clinical experience with fludarabine in hemato-oncology.
Hematol Cell Ther. 1996 Dec;38 Suppl 2:S83-91.
7
Clinical experience with fludarabine in leukaemia.氟达拉滨治疗白血病的临床经验。
Drugs. 1994;47 Suppl 6:39-49. doi: 10.2165/00003495-199400476-00007.
8
New initiatives with fludarabine monophosphate in hematologic malignancies.
Semin Oncol. 1993 Oct;20(5 Suppl 7):13-20.
9
Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies.
Hematol J. 2004;5 Suppl 1:S50-61. doi: 10.1038/sj.thj.6200391.
10
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.氟达拉滨、环磷酰胺和利妥昔单抗用于治疗慢性淋巴细胞白血病或惰性非霍奇金淋巴瘤患者。
Cancer. 2006 Jun 1;106(11):2412-20. doi: 10.1002/cncr.21882.

引用本文的文献

1
Neutrophils unveiled in chronic lymphocytic leukemia.慢性淋巴细胞白血病中发现的中性粒细胞。
Front Immunol. 2025 Aug 20;16:1609754. doi: 10.3389/fimmu.2025.1609754. eCollection 2025.
2
A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers.药物重定位筛选发现氟达拉滨磷酸盐可能成为 N-MYC 过表达神经内分泌前列腺癌的潜在治疗药物。
Cells. 2022 Jul 20;11(14):2246. doi: 10.3390/cells11142246.
3
Low-grade lymphomas: new entities and treatment concepts.
Med Oncol. 1995 Sep;12(3):131-42. doi: 10.1007/BF01571190.